Scholarship@WashULaw
Medicare Coverage of Aducanumab – Implications for State Budgets
Document Type
Article
Publication Date
2021
Publication Title
New England Journal of Medicine
Abstract
Aducanumab (Aduhelm), the controversial $56,000-per-year Alzheimer’s disease drug approved by the Food and Drug Administration (FDA) in June 2021, has the potential to cost the federal government many billions of dollars — more, by one estimate, than it spends on agencies such as the Environmental Protection Agency or the National Aeronautics and Space Administration. The drug’s extraordinary price tag helps explain why, soon after its approval, the Centers for Medicare and Medicaid Services (CMS) opened a national coverage determination to decide whether and under what circumstances Medicare would pay for it.
Keywords
Medicare, Aducanumab, State Budgets
Publication Citation
Rachel Sachs & Nicholas Bagley, Medicare Coverage of Aducanumab – Implications for State Budgets, 385 New Eng. J. Med. 2019 (2021)
Repository Citation
Sachs, Rachel and Bagley, Nicholas, "Medicare Coverage of Aducanumab – Implications for State Budgets" (2021). Scholarship@WashULaw. 298.
https://openscholarship.wustl.edu/law_scholarship/298